Last reviewed · How we verify
NCT02295969
An Observational Study of ORALAIR® (Grass Pollen Allergen Extract From: Cocksfoot, Sweet Vernal, Rye Grass, Meadow Grass, Timothy) Tablet for Sublingual Use in Children 5 to 9 Years of Age With Grass-pollen-induced Allergic Rhinitis With or Without Conjunctivitis
trial testing Oralair in Allergy in 307 participants. Completed in 3 July 2017.
3 July 2017
Quick facts
| Lead sponsor | Stallergenes Greer |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 307 |
| Start date | 1 December 2014 |
| Primary completion | 3 July 2017 |
| Estimated completion | 3 July 2017 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Oralair — full drug profile →
Conditions studied
- Allergy — all drugs for Allergy →
Sponsor
Stallergenes Greer — full company profile →
Who can join
Adults 5 to 9, any sex, with Allergy. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
All adverse events that started on or after the day the first dose of Oralair
Time frame: During 30 days after the date of the first dose
Sponsor's own description
Safety and tolerability of ORALAIR in children 5 to 9 years of age during the first 30 days of treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Real-life safety of 5-grass pollen tablet in 5-to-9-year-old children with allergic rhinoconjunctivitis.
Gerstlauer M, Szepfalusi Z, Golden D, Geng B, et al · · 2019 · cited 7× · PMID 31009701 · DOI 10.1016/j.anai.2019.04.011
Verify or expand the search:
- PubMed search for NCT02295969
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Allergy
Currently open trials in the same condition.
- NCT05997784 — Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing · active not recruiting
- NCT06390878 — Nationwide Research on the Rewilding of Kindergarten Yards · NA · recruiting
- NCT06248957 — SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION · recruiting
- NCT05449756 — A Follow-up Study With Children Who Participated in the TEMPO Study in Their First Year of Life · recruiting
- NCT06192914 — EPAP, Interviewstudy · recruiting
Other Stallergenes Greer trials
Trials by the same sponsor.
- NCT05668390 — Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma · Phase 3 · completed
- NCT06574061 — Evaluation of the Benefits of Sublingual AIT (PRACTIS) · completed
- NCT02443805 — Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR · Phase 3 · completed
- NCT04004351 — Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02295969 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stallergenes Greer
- Last refreshed: 25 July 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02295969.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing